Skip to main content

FDA Approvals

Alunbrig, an Oral Kinase Inhibitor, Receives FDA Approval for NSCLC with ALK Mutation

Rydapt First Drug in Decades Approved by the FDA for Acute Myeloid Leukemia

Stivarga First Drug in a Decade Approved by the FDA for Liver Cancer

Atezolizumab Approved as First-Line Treatment for Advanced Bladder Cancer in Some Patients

Bavencio, a PD-L1 Inhibitor, First Nonchemotherapy Drug Approved for Merkel-Cell Carcinoma

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

Blincyto Receives Expanded Indication to Include Patients with Ph+ B-Cell Precursor ALL

Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Breast Cancer, FDA Approvals, Oncology

Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2016

Page 31 of 53
Results 301 - 310 of 522